October 7, 2022
Below the water line
Since CGM technology came on the scene we have said from day one the adoption seen now is the only the tip of the iceberg. The best part is what’s not seen the much larger market opportunity the huge base of the iceberg below the water line. We have consistently noted that CGM is not just a technology for Type 1 patients or patients following intensive insulin therapy but ALL patients regardless of how they manage their diabetes.
While it’s taken awhile the world is now catching up to what we have been saying all along. Still . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.